Addex konvertiert Wandelanleihen in Namensaktien |
| Tweet |
14.03.2011, Das auf allosterische Modulation spezialisierte Unternehmen Addex Pharmaceuticals (SIX:ADXN) gab heute bekannt, dass die Addex-Nullcoupon-Wandelanleihen (MCN) automatisch in Namensaktien gewandelt worden sind. Dies wurde bereits in einer Pressemitteilung am 14.September 2010 angekündigt.
Der Biotechnology Value Fund, L.P. (BVF) und die Konzerngesellschaften (BVF) haben ihre MCNAnleihen, für den festgesetzten Wandlungspreis von 10,18 CHF, in 1,371,069 Namensaktien konvertiert. Diese wurden aus dem Genehmigten Grundkapital genehmigt und repräsentieren 17% des Aktienkapitals. Folgend dem MCN-Wandel besitzt die BVF circa 30% des Aktienkapitals der Addex.
Medienkontakt:
Chris Maggos Business Development & Communication Addex Pharmaceuticals +41 22 884 15 11 chris.maggos@addexpharma.com
Medienkontakt:
Chris Maggos Business Development & Communication Addex Pharmaceuticals +41 22 884 15 11 chris.maggos@addexpharma.com
Über Addex Pharma SA:
Addex Pharmaceuticals discovers and develops allosteric modulators, small molecule therapeutic agents that may offer more sophisticated ways to normalize biological signaling perturbed by disease compared to classical “orthosteric” agonist or antagonist drugs.
Discovery of allosteric modulators is a scaleable, broadly applicable process that can address a wide variety of therapeutic targets, including some that have not been accessible to classical approaches. Addex has chosen to focus on discovery and development of allosteric modulators that target G-Protein Coupled Receptors (GPCRs), a class of receptors that have proven therapeutic utility in many diseases.
The Addex discovery capability has been validated through three deals with big pharma. The first deal, with Johnson & Johnson, is focused on development of allosteric modulators of metabotropic glutamate receptor 2 (mGluR2) for anxiety and schizophrenia. The second and third deals, with Merck & Co., are focused on developing allosteric modulators targeting mGluR4 and mGluR5 to treat Parkinson's disease and schizophrenia, respectively.
The company has a growing pipeline of products in clinical or preclinical development for major market indications including: gastroesophageal reflux disease (GERD); migraine; schizophrenia and Parkinson's disease.
Addex is located in Geneva, Switzerland and has a subsidiary in Archamps, France. The rapidly growing company, which had about 100 employees as of the second quarter of 2008, is actively hiring at both locations.
Discovery of allosteric modulators is a scaleable, broadly applicable process that can address a wide variety of therapeutic targets, including some that have not been accessible to classical approaches. Addex has chosen to focus on discovery and development of allosteric modulators that target G-Protein Coupled Receptors (GPCRs), a class of receptors that have proven therapeutic utility in many diseases.
The Addex discovery capability has been validated through three deals with big pharma. The first deal, with Johnson & Johnson, is focused on development of allosteric modulators of metabotropic glutamate receptor 2 (mGluR2) for anxiety and schizophrenia. The second and third deals, with Merck & Co., are focused on developing allosteric modulators targeting mGluR4 and mGluR5 to treat Parkinson's disease and schizophrenia, respectively.
The company has a growing pipeline of products in clinical or preclinical development for major market indications including: gastroesophageal reflux disease (GERD); migraine; schizophrenia and Parkinson's disease.
Addex is located in Geneva, Switzerland and has a subsidiary in Archamps, France. The rapidly growing company, which had about 100 employees as of the second quarter of 2008, is actively hiring at both locations.
Weitere Informationen und Links:
Newsletter abonnieren
Auf diesem Link abonnieren Sie unseren Newsletter und sind stets aktuell informiert.
Eigene News publizieren
Haben Sie eine aktuelle Firmeninformation oder ein Angebot, dass Sie hier publizieren möchten?
Auf diesem Link erfassen Sie die entsprechenden Informationen.
TOP NEWS - powered by Help.ch
Sicherheit bei Beschaffungen des Bundes: SEPOS zeigt Massnahmen auf Staatssekretariat für Sicherheitspolitik SEPOS, 01.05.2025
1004 Handelsregister-Meldungen vom 01.05.2025, heutige Publikationen im Schweizer Handelsamtsblatt SHAB Portal Helpnews.ch, 01.05.2025
214 Firmengründungen am 01.05.2025 – Aktuelle Publikationen im Schweizer Handelsamtsblatt (SHAB) Portal Helpnews.ch, 01.05.2025
Aktueller Jackpot: CHF 2'021'418
Teilnehmer von
